Evidence map›Paper›PMID 25378645›Full record

Trial reportScience translational medicine2014

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Leo Swadling, Stefania Capone, Richard D Antrobus, Anthony Brown, Rachel Richardson, Evan W Newell, John Halliday, Christabel Kelly, Dan Bowen, Joannah Fergusson and 15 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 2 pooled it
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 2 syntheses or guidelines pooled it, 333 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Trial
  12. Review
  13. Article
  14. Tracking Canada's 2015 vaccine research and development priorities: Where are we a decade later?Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025
    Review
  20. Review

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 4 countries.

Leo SwadlingNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Stefania CaponeReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Richard D AntrobusNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Anthony BrownNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Rachel RichardsonNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Evan W NewellDepartment of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA. Singapore Immunology Network, Singapore 138648, Singapore.
John HallidayNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. National Institute for Health Research Oxford Biomedical Research Centre, and Translational Gastroenterology Unit, Oxford OX3 7LE, UK.
Christabel KellyNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. National Institute for Health Research Oxford Biomedical Research Centre, and Translational Gastroenterology Unit, Oxford OX3 7LE, UK.
Dan BowenNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Joannah FergussonNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Ayako KuriokaNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.
Virginia AmmendolaReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Mariarosaria Del SorboReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Fabiana GrazioliReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Maria Luisa EspositoReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Loredana SianiReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Cinzia TraboniReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Adrian HillNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Stefano CollocaReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Mark DavisDepartment of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
Alfredo NicosiaReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy. CEINGE, via Gaetano Salvatore 486, 80145 Naples, Italy. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Riccardo CorteseOkairos AG, 4051 Basel, Switzerland.
Antonella FolgoriReiThera Srl (ex Okairos), Viale Città d'Europa 679, 00144 Rome, Italy.
Paul KlenermanNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. National Institute for Health Research Oxford Biomedical Research Centre, and Translational Gastroenterology Unit, Oxford OX3 7LE, UK.
Eleanor BarnesNuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK. National Institute for Health Research Oxford Biomedical Research Centre, and Translational Gastroenterology Unit, Oxford OX3 7LE, UK. ellie.barnes@ndm.ox.ac.uk.
University of Oxford · GBStanford University · USCeinge Biotecnologie Avanzate (Italy) · ITJenner Institute · GB

Funding

Department of HealthMedical Research Council MR/K010239/1Wellcome Trust 091663
6 · The paper itself

Abstract

A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV infects millions of people worldwide and is a leading cause of liver cirrhosis and hepatocellular cancer. Animal challenge experiments, immunogenetics studies, and assessment of host immunity during acute infection highlight the critical role that effective T cell immunity plays in viral control. In this first-in-man study, we have induced antiviral immunity with functional characteristics analogous to those associated with viral control in natural infection, and improved upon a vaccine based on adenoviral vectors alone. We assessed a heterologous prime-boost vaccination strategy based on a replicative defective simian adenoviral vector (ChAd3) and modified vaccinia Ankara (MVA) vector encoding the NS3, NS4, NS5A, and NS5B proteins of HCV genotype 1b. Analysis used single-cell mass cytometry and human leukocyte antigen class I peptide tetramer technology in healthy human volunteers. We show that HCV-specific T cells induced by ChAd3 are optimally boosted with MVA, and generate very high levels of both CD8(+) and CD4(+) HCV-specific T cells targeting multiple HCV antigens. Sustained memory and effector T cell populations are generated, and T cell memory evolved over time with improvement of quality (proliferation and polyfunctionality) after heterologous MVA boost. We have developed an HCV vaccine strategy, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.

Indexed as

Immunologic MemoryAdenoviridaeAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationCells, CulturedEnglandEnzyme-Linked Immunospot AssayHealthy VolunteersHepacivirusHepatitis CHepatitis C AntibodiesHistocompatibility Antigens Class IHumansInterferon-gamma Release TestsHepatitis C AntibodiesHistocompatibility Antigens Class IMVA vaccineVaccines, DNAViral Hepatitis VaccinesViral Vaccines

Identifiers

PMID25378645
PMCPMC4669853
OpenAlexW2038281342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.